Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MOR NYSE:SBS TSE:SHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$5.52-2.9%$5.63$3.79▼$7.16$19.99B0.664.93 million shs7.83 million shsSHLSource Energy ServicesC$0.00C$0.00▼C$0.00N/AN/AN/AN/A7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMORMorphoSys0.00%0.00%0.00%0.00%0.00%SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp-2.82%-2.99%-4.82%-96.65%-94.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$5.52-2.9%$5.63$3.79▼$7.16$19.99B0.664.93 million shs7.83 million shsSHLSource Energy ServicesC$0.00C$0.00▼C$0.00N/AN/AN/AN/A7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMORMorphoSys0.00%0.00%0.00%0.00%0.00%SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp-2.82%-2.99%-4.82%-96.65%-94.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMORMorphoSys 0.00N/AN/AN/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp 3.33Buy$183.003,218.22% UpsideSHLSource Energy Services 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest DRW3, SBS, SHL, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/11/2026SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (A-) ➝ Buy (B)(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$6.82B2.85$0.42 per share13.09$2.16 per share2.55SHLSource Energy ServicesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$1.52B$0.3814.383.191.7124.25%16.38%6.83%8/12/2026 (Estimated)SHLSource Energy ServicesN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest DRW3, SBS, SHL, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$0.0899N/AN/AN/A$1.31 billionN/A5/7/2026Q1 2026SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$0.0820$0.02-$0.0620$0.10$1.28 billion$1.16 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMORMorphoSysN/AN/AN/AN/AN/ASBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp$0.101.81%+30.26%26.32%N/ASHLSource Energy ServicesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMORMorphoSys4.981.381.38SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp1.071.741.73SHLSource Energy ServicesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMORMorphoSys18.38%SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp10.62%SHLSource Energy ServicesN/AInsider OwnershipCompanyInsider OwnershipMORMorphoSys0.05%SBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp1.00%SHLSource Energy ServicesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableSBSCompanhia de saneamento Basico Do Estado De Sao Paulo - Sabesp8,6783.52 billion3.48 billionOptionableSHLSource Energy ServicesN/AN/AN/ANot OptionableDRW3, SBS, SHL, and MOR HeadlinesRecent News About These CompaniesHomeland Nickel Hires U.S. Investor Relations Firm to Boost Market VisibilityMarch 25, 2026 | tipranks.comHomeland Nickel Expands Oregon Portfolio and Ties With Patriot NickelMarch 17, 2026 | tipranks.comHomeland Nickel to Gain Wider Investor Base Through Noble Share DistributionFebruary 12, 2026 | tipranks.comHomeland Nickel Names Jordan Black Corporate Secretary as Errol Farr Steps DownJanuary 25, 2026 | tipranks.comHomeland Nickel Says No Material Change Behind Surge in Trading ActivityJanuary 21, 2026 | tipranks.comHomeland Nickel Grants 650,000 Stock Options to ConsultantsOctober 9, 2025 | tipranks.comHomeland Nickel Partners with Brazilian Nickel for Oregon Project DevelopmentOctober 7, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026MarketBeat Week in Review – 07/13- 07/17By MarketBeat Staff | July 18, 2026Why Welltower's Growth Story Might Outrun Its Rich ValuationBy Chris Markoch | July 13, 2026DRW3, SBS, SHL, and MOR Company DescriptionsMorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 07/27/2026MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp NYSE:SBS$5.52 -0.17 (-2.90%) Closing price 07/28/2026 03:59 PM EasternExtended Trading$5.53 +0.01 (+0.25%) As of 05:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Companhia de Saneamento Basico do Estado de Sao Paulo SABESP engages in the provision of water and sewage service. It also offers advisory services on the rational use of water, planning and commercial, and financial and operational management. The company was founded on September 6, 1973 and is headquartered in São Paulo, Brazil.Source Energy Services TSE:SHLHomeland Nickel is a Canadian-based mineral exploration company focused on critical metal resources with nickel projects in Oregon, United States and copper and gold projects in Newfoundland, Canada. The Company holds a significant portfolio of mining securities including 742,095 shares of Canada Nickel Company Inc. (TSX-V: CNC), 9.960 million shares of Noble Mineral Exploration Inc. (TSX-V: NOB), 11.477 million shares of Benton Resources Inc. (TSX-V: BEX), 139,767 shares of Vinland Lithium Inc. (TSX-V: VLD) and 2.761 million shares of Magna Terra Minerals Inc. (TSX-V: MTT). Homeland Nickel's common shares trade on the TSX Venture Exchange under the symbol 'SHL'. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
